New cancer therapies. Uncertain?

Dementia.Incurable?

Gene Therapies. Unaffordable?

We are part of the solution.

Sartorius is part of the solution in the fight against many diseases

Our biopharma customers are working hard to develop and eventually manufacture new drugs, therapeutics or vaccines to improve people‘s lives. And we are at their sides to help them simplify their processes, obtain results faster and produce medications more efficiently.

In a time, where making a contribution to global health has never been more important, Sartorius is part of the solution in the fight against Covid-19. Cancer. Dementia. And many other diseases.

We are a growing team of  more than 14,000 - and are looking for people who share our ambition. Join our team, make a contribution and grow with us.

In 2020, around 200 companies and institutions joined the race for developing vaccines against the coronavirus. While this ambition was successful in record speed, a new challenge then became more pressing: Billions of vaccine doses had been ordered around the world, leaving biopharma companies with the task of quickly switching from small- to large-scale manufacturing.

Sartorius is working with most of these companies and institutions. In fact, whether lab equipment like pipettes and filters or bioprocessing technologies for manufacturing are needed, our products go into the making of most vaccines around the world.

Learn more about Sartorius' solutions in fighting Covid-19.

Every year, an estimated 10 million people die of cancer, making it one of the leading causes of death in the world. And cancer rates are rising. While new therapies seem possible, they still remain uncertain for many types of cancer.

At Sartorius, we collaborate closely with customers to help them develop new therapies and bring medications safely and quickly to the patient.

Find out more about Sartorius' contribution to cell therapy.

Fifty million people in the world have dementia, there are nearly 10 million new cases every year and with the population growing older, we are facing ever-increasingly rising numbers in the near future. So far, there is no cure available.

At Sartorius, we support our customers in simplifying and shortening the lengthy and difficult search for active ingredients so that at some point, patients will not only be treated, but might even be cured.

Gene therapies are one of the most promising concepts of life science research. Take rare diseases.

About 6,000 diseases worldwide are considered rare because fewer than one in 10,000 people suffer from them. Spinal muscular atrophy is a prime example. One in 6,000 to 10,000 babies are born with this neuromuscular disorder. Untreated, the disease will usually lead to death within a few years. And while there is a cure, just a single dose required for the respective gene therapy today costs 2.1 million U.S. dollars.

At Sartorius, we help our customers speed up development processes and reduce manufacturing costs, so that such therapeutics reach more patients faster and remain affordable.

Learn more about Sartorius' solutions for the development and manufacturing of gene therapies.


1,000+ opportunities to be part of the solution: Find your new job.

Job Opportunities

Couldn't find an open position? Register and set up job alert

About Sartorius

Learn More

Professionals

Learn More